Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:14 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma
NCT03059147 · SignalRX Pharmaceuticals, Inc. · PHASE1 · terminated · last registry update 2022-05-18 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of recruitment and sponsor's priority changes” | – | Registry record, SignalRX Pharmaceuticals, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PDCD1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-03-23Results posted on the registry: City of Hope Medical Center, Cyclophosphamide + Cytokine-based Biologic Agent IRX-2 (NCT03918499)
- 2022-12-01Phase 3 first posted: Gilead Sciences, Sacituzumab govitecan-hziy (SG) + Pembrolizumab (NCT05633654)
- 2022-11-08Phase 3 first posted: Regeneron Pharmaceuticals, Fianlimab + Cemiplimab (NCT05608291)
- 2022-09-27Phase 3 first posted: Daiichi Sankyo, Datopotamab Deruxtecan + Pembrolizumab (NCT05555732)
- 2022-08-30Phase 3 first posted: Hutchmed, fruquintinib+sintilimab + axitinib / everolimus (NCT05522231)
- 2022-06-30Results posted on the registry: City of Hope Medical Center, Pembrolizumab (NCT02830594)
- 2022-06-23Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Sintilimab + Carboplatin (NCT05429463)
- 2022-01-21Phase 3 first posted: ARCAGY/ GINECO GROUP, Carboplatin-Paclitaxel + Dostarlimab (NCT05201547)
- 2021-09-17Phase 3 first posted: AstraZeneca, Trastuzumab Deruxtecan + Cisplatin (NCT05048797)
- 2021-09-14Results posted on the registry: Immunocore Ltd, IMCgp100 + Dacarbazine (NCT03070392)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision